Novo Nordisk Total Non-Operating Income/Expense 2010-2024 | NVO

Novo Nordisk annual/quarterly total non-operating income/expense history and growth rate from 2010 to 2024. Total non-operating income/expense can be defined as the sum of all non-operating expenses for the given industry.
  • Novo Nordisk total non-operating income/expense for the quarter ending September 30, 2024 was $0.083B, a 50.66% decline year-over-year.
  • Novo Nordisk total non-operating income/expense for the twelve months ending September 30, 2024 was $0.129B, a 75.94% increase year-over-year.
  • Novo Nordisk annual total non-operating income/expense for 2023 was $0.305B, a 137.47% decline from 2022.
  • Novo Nordisk annual total non-operating income/expense for 2022 was $-0.814B, a 1273.13% decline from 2021.
  • Novo Nordisk annual total non-operating income/expense for 2021 was $0.069B, a 145.46% decline from 2020.
Novo Nordisk Annual Total Non-Operating Income/Expense
(Millions of US $)
2023 $305
2022 $-814
2021 $69
2020 $-153
2019 $-589
2018 $56
2017 $-44
2016 $-94
2015 $-887
2014 $-71
2013 $186
2012 $-287
2011 $-84
2010 $-108
2009 $-177
Novo Nordisk Quarterly Total Non-Operating Income/Expense
(Millions of US $)
2024-09-30 $83
2024-06-30 $-87
2024-03-31 $10
2023-12-31 $122
2023-09-30 $168
2023-06-30 $53
2023-03-31 $-39
2022-12-31 $-109
2022-09-30 $-291
2022-06-30 $-228
2022-03-31 $-185
2021-12-31 $-86
2021-09-30 $-22
2021-06-30 $22
2021-03-31 $155
2020-12-31 $117
2020-09-30 $-18
2020-06-30 $-62
2020-03-31 $-189
2019-12-31 $-116
2019-09-30 $-121
2019-06-30 $-197
2019-03-31 $-155
2018-12-31 $-77
2018-09-30 $-105
2018-06-30 $47
2018-03-31 $192
2017-12-31 $70
2017-09-30 $66
2017-06-30 $-110
2017-03-31 $-70
2016-12-31 $-40
2016-09-30 $-18
2016-06-30 $16
2016-03-31 $-53
2015-12-31 $-117
2015-09-30 $-275
2015-06-30 $-287
2015-03-31 $-208
2014-12-31 $-146
2014-09-30 $-20
2014-06-30 $47
2014-03-31 $49
2013-12-31 $78
2013-09-30 $55
2013-06-30 $17
2013-03-31 $37
2012-12-31 $-22
2012-09-30 $-85
2012-06-30 $-123
2012-03-31 $-58
2011-12-31 $-90
2011-09-30 $-10
2011-06-30 $39
2011-03-31 $-23
2010-12-31 $-29
2010-09-30 $-62
2010-06-30 $-47
2010-03-31 $30
2009-12-31 $-68
2009-09-30 $-33
2009-06-30 $-38
2009-03-31 $-38
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $481.063B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51